KALV insider trading
NasdaqGM HealthcareKalVista Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Company website: www.kalvista.com
KALV insider activity at a glance
FilingIQ has scored 559 insider transactions for KALV since Nov 21, 2016. The most recent filing in our index is dated May 12, 2026.
Across the full history, 49 open-market purchases
and 280 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on KALV insider trades is 56.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest KALV Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding KALV
Frequently asked
- How many insider trades does FilingIQ track for KALV?
- FilingIQ tracks 559 Form 4 insider transactions for KALV (KalVista Pharmaceuticals, Inc.), covering filings from Nov 21, 2016 onwards. 53 of those were filed in the last 90 days.
- Are KALV insiders net buyers or net sellers?
- Across the full Form 4 history for KALV, 49 transactions (9%) were open-market purchases and 280 (50%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does KALV insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is KALV in?
- KalVista Pharmaceuticals, Inc. (KALV) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $791.55M.
Methodology & sources
Every KALV insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.